We are live on ! Find out more
Charles Schwab

Charles Schwab Portfolio holdings

AUM $654B
1-Year Est. Return 26.35%
 

Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.

This Fund
S&P 500
This Quarter Est. Return
-12.91%
1 Year Est. Return
+26.35%
3 Year Est. Return
+83.88%
5 Year Est. Return
+111.55%
10 Year Est. Return
+435.01%
AUM
$131B
AUM Growth
-$19.5B
Cap. Flow
+$2.76B
Cap. Flow %
2.11%
Top 10 Hldgs %
14.61%
Holding
3,199
New
67
Increased
1,772
Reduced
1,049
Closed
53

Top Buys

Rank Stock Value
1
LIN icon
Linde
LIN
+$361M
2
CVS icon
CVS Health
CVS
+$180M
3
CI icon
Cigna
CI
+$158M
4
MSFT icon
Microsoft
MSFT
+$102M
5
AMZN icon
Amazon
AMZN
+$90M

Sector Composition

Rank Sector Weight
1 Technology 15.86%
2 Financials 13.99%
3 Healthcare 13.63%
4 Industrials 10.39%
5 Consumer Discretionary 9.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ASUR icon
3076
Asure Software
ASUR
$240M
$121K ﹤0.01%
23,660
-3,700
-14% -$30.5K
FTK icon
3077
Flotek Industries
FTK
$847M
$121K ﹤0.01%
18,443
+2,410
+15% +$24.4K
TLGT
3078
DELISTED
Teligent, Inc
TLGT
$120K ﹤0.01%
8,720
GEN
3079
DELISTED
Genesis Healthcare, Inc.
GEN
$120K ﹤0.01%
101,000
STRO icon
3080
Sutro Biopharma
STRO
$411M
$119K ﹤0.01%
+1,311
New +$158K
ACGN
3081
DELISTED
Aceragen Inc
ACGN
$118K ﹤0.01%
2,502
ALNA
3082
DELISTED
Allena Pharmaceuticals
ALNA
$118K ﹤0.01%
21,600
CHRA
3083
DELISTED
Charah Solutions, Inc Common Stock
CHRA
$117K ﹤0.01%
1,395
LLEX
3084
DELISTED
Lilis Energy, Inc. Common Stock
LLEX
$117K ﹤0.01%
85,300
-10,300
-11% -$27.9K
FCEL icon
3085
FuelCell Energy
FCEL
$1.89B
$116K ﹤0.01%
585
+164
+39% +$46.9K
ADMA icon
3086
ADMA Biologics
ADMA
$2.01B
$105K ﹤0.01%
43,700
MTEM
3087
DELISTED
Molecular Templates, Inc.
MTEM
$104K ﹤0.01%
1,702
+575
+51% +$40.1K
IO
3088
DELISTED
ION Geophysical Corporation
IO
$103K ﹤0.01%
19,800
-36,675
-65% -$373K
MRSN
3089
DELISTED
Mersana Therapeutics
MRSN
$100K ﹤0.01%
980
-144
-13% -$22.8K
SN
3090
DELISTED
Sanchez Energy Corporation
SN
$100K ﹤0.01%
366,792
-78,637
-18% -$101K
HZN
3091
DELISTED
Horizon Global Corporation
HZN
$99K ﹤0.01%
68,740
-26,252
-28% -$102K
SNCR
3092
DELISTED
Synchronoss Technologies
SNCR
$98K ﹤0.01%
+1,762
New +$96.8K
RMNI icon
3093
Rimini Street
RMNI
$454M
$97K ﹤0.01%
18,800
CRVS icon
3094
Corvus Pharmaceuticals
CRVS
$1.11B
$96K ﹤0.01%
25,900
MBIO icon
3095
Mustang Bio
MBIO
$4.5M
$93K ﹤0.01%
42
ZOM
3096
DELISTED
Zomedica Corp.
ZOM
$91K ﹤0.01%
73,900
RNAC icon
3097
Cartesian Therapeutics
RNAC
$227M
$90K ﹤0.01%
1,123
-137
-11% -$31.3K
SPRO icon
3098
Spero Therapeutics
SPRO
$69.5M
$90K ﹤0.01%
14,527
VRCA icon
3099
Verrica Pharmaceuticals
VRCA
$90.4M
$90K ﹤0.01%
1,097
EQ icon
3100
Equillium
EQ
$147M
$87K ﹤0.01%
+10,650
New +$148K

Similar funds

Charles Schwab's Q4 2018 Portfolio in Review

As of Q4 2018, Charles Schwab held 3,199 positions worth $131B, down 13% from $150B the previous quarter. Its ten largest holdings account for 15% of the portfolio.

Trading was light in Q4 2018: portfolio turnover was 3.8%. Charles Schwab opened 67 new positions and exited 53, leaving the 3,199-position portfolio largely intact.

By sector, the portfolio is most concentrated in Technology at 16% of assets, down from 17% a quarter earlier, followed by Financials and Healthcare.

  • Charles Schwab's largest Q4 2018 buy was Linde: 2,286,208 shares worth $357M.
  • Charles Schwab added most to CVS Health in Q4 2018, an estimated $180M increase.
  • Charles Schwab's biggest Q4 2018 reduction was Qualcomm, cutting an estimated $42.7M.
  • Charles Schwab fully exited Express Scripts Holding Company in Q4 2018, selling an estimated $301M.
  • Charles Schwab's ten largest holdings make up 15% of its $131B portfolio in Q4 2018.
  • Charles Schwab opened 67 new positions and closed 53 in Q4 2018.
  • Charles Schwab's portfolio value fell 13% quarter-over-quarter to $131B.

Based on Charles Schwab's 13F filing for Q4 2018, filed 14 Feb 2019.